Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Cofactor Supplementation in NAFLD
NCT04330326Phase 2Completed
- Sponsor
- ScandiBio Therapeutics
- Start
- Jul 2019
- Primary completion
- Jul 2020
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by ScandiBio Therapeutics. Primary endpoint: Magnetic Resonance Spectroscopy (MRS) Measurement at 10 weeks. Started Jul 2019; status: completed.
02
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04330326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04330326.